In Case You Missed It Wednesday: Biotech Drags on Nasdaq as Dow Sets Record
Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large phase III clinical trial.

If you'd like to receive "In Case You Missed It" in your email inbox every evening, please register for TheStreet Alerts and follow me.

Another day, another record close for the Dow Jones Industrial Average.

The record close came as minutes from the November Federal Reserve meeting were released, all but solidifying that a December rate hike will take place, and as gold, a typical safe haven commodity for those fearing an economic down-turn may be on the horizon, continued a decline since its election run-up to $1,300 per ounce.

The Trump rally aside, positive economic data, including orders for long-lasting goods in the U.S. (they increased 4.8% in October compared to projections of just 1.5%) also helped pushed the Dow to another record-setting day. 

Still not all that glitters is gold. Healthcare continued to struggle Wednesday, although this time for a reason other than fears of what Donald Trump may do to the Affordable Care Act. Biotech led the decline, after a late-stage trial of an Alzheimer's drug from Eli Lilly (LLY) didn't meet its primary endpoint.

So while Wall Street eyed the record close, TheStreet and its affiliates were gearing up for the holiday shopping season--helping you navigate the markets and the biggest winners and losers from the holiday shopping season. And, that's not all.

Here are the highlights:

Retailers May Have Just Gotten an Early Holiday Gift From Consumers
Consumers look to already be out there holiday shopping fairly solidly, according to early data. Full story

Amazon Sports Service Won't Eat Disney's Lunch, but It Doesn't Have To
With TV networks controlling the rights to the best sports content, Amazon's (AMZN) rumored sports package might not be too disruptive. But it could give Prime members another reason to renew. Full story

Tweet of the Day:

Eli Lilly: Is there life after a big gap to the downside? --Kamich https://t.co/RhgAHlfeTY

— Jim Cramer (@jimcramer) November 23, 2016

Which Chipmakers Might Get Acquired After Macom-AppliedMicro Deal
Deal season may be over for major chipmakers, but some analysts believe the next round could come from smaller, more specialized semiconductor companies. Full story

Warren Urges GAO to Review 'Chaotic' Trump Transition
The Massachusetts Democrat urged the government accountability office to study the president-elect's process for picking cabinet secretaries and agency officials, charging that it is rife with conflicts. Full story

Chart of the Day: Starbucks May Have to Pull Back Before Closing the Gap

 

The stock has rallied 12% in 12 days and may need to regroup. (SBUX) Full story

UK's Hammond Conjures Up Cash for Technology, Infrastructure as Debt Rises
Britain's new finance chief says he wants to protect technology startups from early takeovers. Full story 

Video of the Day: 4 Hot Stocks to Watch From the Macy's Thanksgiving Day Parade

TheStreet uncovered a few stocks that are featured prominently in the Macy's Thanksgiving Day Parade. Full story

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief